Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules

Executive Summary

An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads

You may also be interested in...



US FDA Calls Foul On CSL Behring Hemophilia Drug Promo

Idelvion promotional materials misleadingly imply that patients can engage in high-risk activity without consequences; first letter from US biologics promo branch in three years.

Pfizer Revises Zoloft Ad After FDA Cites Lack Of Suicide Information

Pfizer is revising Zoloft (sertraline) advertisements after FDA cited the company for not incorporating updated risk information in a print ad for the antidepressant

Pfizer Revises Zoloft Ad After FDA Cites Lack Of Suicide Information

Pfizer is revising Zoloft (sertraline) advertisements after FDA cited the company for not incorporating updated risk information in a print ad for the antidepressant

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045242

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel